cancer susceptibility 22Genealiases: LINC01373 · LincRNA-ENST00000515084 · TCONS_00024290
Q-omics provides the consensus-scored CASC22 profile across patient tissues and cancer cell-line models. CASC22 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, CASC22 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, CASC22 RNA expression shows 6,335 significant gene co-expression associations, with the highest sampling consensus in BLCA. Together, these results highlight THCA, KIRC, and BLCA as cancer lineages where CASC22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CASC22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CASC22 survival associations across molecular data types. CASC22 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CASC22 RNA expression–survival associations across cancer types. High CASC22 expression shows unfavorable associations in THCA, BRCA, STAD, LUAD and THYM, but favorable associations in BLCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for CASC22 RNA expression.
This table summarizes CASC22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CASC22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CASC22 shows lower tumor expression in KIRC and KIRP and higher tumor expression in LIHC, KICH and BRCA. The KIRC box plot shows higher CASC22 RNA expression in normal versus tumor tissue (log2 FC = −0.208, t-test p < 0.001).
This table shows molecular features associated with CASC22 in patient tissues and cancer cell lines. In patient samples, CASC22 shows the broadest associations at the RNA and protein expression levels, with BLCA recurring as the lineage with the largest associated feature set.
